Skip to main content

Press Releases and Ad-hoc Announcements

24 April 2025
PR: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
PDF
26 March 2025
PR: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
PDF
21 March 2025
PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
PDF
13 March 2025
PR: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
PDF
13 March 2025
AH: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
PDF
13 January 2025
PR: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
PDF
06 November 2024
PR: Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
PDF
24 October 2024
PR: Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
PDF
10 October 2024
PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
PDF
01 October 2024
PR: Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
PDF
01 October 2024
AH: Heidelberg Pharma AG Announces Updated Guidance
PDF
23 September 2024
PR: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
PDF
11 July 2024
PR: Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
PDF
21 June 2024
PR: Heidelberg Pharma reports on the results of the Annual General Meeting 2024
PDF
18 June 2024
AH: Heidelberg Pharma AG Announces Updated Guidance
PDF
23 May 2024
PR: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
PDF
25 April 2024
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
PDF
05 April 2024
PR: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
PDF
27 March 2024
PR: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
PDF
25 March 2024
PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
PDF
19 March 2024
PR: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
PDF
18 March 2024
PR: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
PDF
06 March 2024
PR: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
PDF
04 March 2024
PR: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
PDF
04 March 2024
AH: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
PDF
29 November 2023
PR: Heidelberg Pharma Announces Changes to the Executive Management Board
PDF
29 November 2023
AH: Heidelberg Pharma Announces Changes to the Executive Management Board
PDF
15 November 2023
PR: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
PDF
02 November 2023
PR: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
PDF
12 October 2023
PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2023
PDF